Bayer Eyes More Link-Ups Like Loxo After Pipeline Blips
Litigation woes at Monsanto are casting a shadow over Bayer but despite the news of some discontinued projects, the German major sees pharma as an integral component and will keep investing in its pipeline.
You may also be interested in...
Top-line results from the Phase III ARAMIS study indicate the next-generation oral androgen receptor antagonist, darolutamide, has met its primary endpoint and could provide a boost for Finland's multinational and now pure-play pharma company, Orion, plus Bayer too.
Several medicines referred to the European Medicines Agency on issues relating to safety or benefit-risk profile are being discussed by the agency's medicines evaluation committee, the CHMP, this week.
Not for the first time this decade, the German major has been warned by the US FDA about its manufacturing processes and sorting out the problems could affect supplies of some big-selling products such as the blood pressure treatment Adalat and the erectile dysfunction drug Levitra.